Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “April 30, 2024”.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 174    

Filtered results: 174

Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model

Cherney D, et al. Journal of Medical Economics. 2025. doi:10.1080/13696998.2025.2451526

Cherney D, Drzewiecka A, Folkerts K, Levy P, Millier A, Morris S, 23 01 2025

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Mentz RJ, et al. Eur J Heart Fail. 2025. doi:10.1002/ejhf.3569

Mentz RJ, Anker SD, Pitt B, Rossing P, Ruilope LM, Gebel M, Kolk, 17 01 2025

Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and type 2 diabetes

Zannad F, et al. J Intern Med. 2024; 1–18.

Zannad F., McGuire DK., and Ortiz A., 31 12 2024

Clinical profile and treatment adherence in patients with type 2 diabetes and chronic kidney disease who initiate an SGLT2 inhibitor: A multi-cohort study

Johannes CB, et al. Diabetes Ther. 2024. doi: 10.1007/s13300-024-01671-x

Johannes CB., Ziemiecki R., Pladevall-Vila M., Ebert N., Kovesdy, 17 12 2024

Clinical implications of mineralocorticoid receptor overactivation

Nigwekar SU, et al. Clinical Kidney Journal. 2025. doi:10.1093/ckj/sfae346

El Mouhayyar C., Chhikara M., Tang MY., and Nigwekar SU., 24 11 2024

The role of finerenone in optimizing cardiovascular-kidney metabolic health: Everything PCPs should know

Wright EE, et al. Fed Pract. 2024;41(suppl 6):S41-S46

Wright EE., Frady RB., and Uko C., 01 11 2024

The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease

Escobar Vasco MA, et al. Diabetes Obes Metab. 2024;26(10):4135-4146.

Escobar Vasco MA, 09 10 2024

Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial

Mc Causland FR, et al. JACC. 2024;doi.org/10.1016/j.jacc.2024.10.091.

Mc Causland FR, 01 10 2024

FOUNTAIN: a modular research platform for integrated real-world evidence generation

Oberprieler NG, et al. BMC Med Res Methodol. 2024;24(1):224.

Oberprieler NG, 01 10 2024

Slowing the progression of diabetic and non-diabetic kidney disease: A summary of the current evidence base for sodium-glucose co-transporter-2 inhibitors

Rotbain Curovic V, et al. Diabetes Obes Metab. 2024;26 Suppl 6:22-32.

Rotbain Curovic V, 01 10 2024